3-(2-甲氧羰基乙基)苯基硼酸 | 833472-82-5

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-(2-甲氧羰基乙基)苯基硼酸
• 中文别名: 3-(3-硼苯基)丙酸甲酯；3-(2-甲氧基羰基乙基)苯硼酸
• 英文名称: (3-(3-methoxy-3-oxopropyl)phenyl)boronic acid
• 英文别名: 3-(2-methoxycarbonylethyl)phenylboronic acid,；3-(3-methoxy-3-oxopropyl)phenylboronic acid；(3-(2-methoxycarbonylethyl)phenyl)boronic acid；[3-(3-methoxy-3-oxopropyl)phenyl]boronic acid
• CAS: 833472-82-5
• 化学式: C₁₀H₁₃BO₄
• mdl: MFCD04115648
• 分子量: 208.022
• InChiKey: IPXZIWCEVNDHFD-UHFFFAOYSA-N

物化性质

• 熔点：
  96-100°C
• 沸点：
  371.4±44.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(2-Methoxycarbonylethyl)phenylboronic acid
Synonyms: Methyl 3-(3-boronophenyl)propionate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(2-Methoxycarbonylethyl)phenylboronic acid
CAS number: 833472-82-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H13BO4
Molecular weight: 208.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(2-甲氧羰基乙基)苯基硼酸 在 甲醇 、 4-二甲氨基吡啶 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 正庚烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.0h， 生成 (S)-4-[16-difluoromethoxy-17-fluoro-13-methyl-3,12-dioxo-2,13-diazatricyclo[13.3.1.1^6,10]icosa-1(19),6,8,10(20),15,17-hexaene-11-ylamino]-benzonitrile
  参考文献：
  名称：

  [EN] MACROCYCLIC FACTOR VIIA INHIBITORS
  [FR] INHIBITEURS DU FACTEUR VIIA MACROCYCLIQUES

  摘要：

  公开号：

  WO2014201073A9
• 作为产物：
  描述：

  3-(3-溴苯基)丙酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 氯化亚砜 、 potassium acetate 作用下， 以 1,4-二氧六环 、 二甲基亚砜 为溶剂， 反应 3.0h， 生成 3-(2-甲氧羰基乙基)苯基硼酸
  参考文献：
  名称：

  [EN] MACROCYCLIC FACTOR VIIA INHIBITORS
  [FR] INHIBITEURS DU FACTEUR VIIA MACROCYCLIQUES

  摘要：

  公开号：

  WO2014201073A9

文献信息

• [EN] INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF<br/>[FR] MACROCYCLES CONTENANT DE L'INDAZOLE ET UTILISATIONS THÉRAPEUTIQUES ASSOCIÉES
  申请人：SAMUMED LLC

  公开号：WO2019241540A1

  公开（公告）日：2019-12-19

  Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

  公开了用于治疗各种疾病和病理的Indazole大环化合物的化学式（I）。更具体地，本发明涉及使用Indazole大环化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理/疾病/疾病。还提供了治疗与Wnt相关疾病状态的方法。化学式（I）
• [EN] ARYL AND ARYLALKYL SUBSTITUTED PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS<br/>[FR] PYRAZOLYLE SUBSTITUÉ PAR UN ARYLE ET ARYLALKYLE ET PYRIMIDINYL ÉNONES TRICYCLIQUES COMME MODULATEURS ANTIOXYDANTS DE L'INFLAMMATION
  申请人：ABBVIE INC

  公开号：WO2015112792A1

  公开（公告）日：2015-07-30

  The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein R1, R2, R3, R4, R5, R6, m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

  本申请涉及：(a) 公式(I)的化合物及其盐，其中R1、R2、R3、R4、R5、R6、m、n、X和Y如规范中所定义；(b) 包含这些化合物和盐的组合物；以及(c) 使用这些化合物、盐和组合物的方法，特别是用于治疗和预防与氧化应激和炎症相关的疾病。
• Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy
  作者：William McCoull、Andrew Bailey、Peter Barton、Alan M. Birch、Alastair J. H. Brown、Hayley S. Butler、Scott Boyd、Roger J. Butlin、Ben Chappell、Paul Clarkson、Shelley Collins、Robert M. D. Davies、Anne Ertan、Clare D. Hammond、Jane L. Holmes、Carol Lenaghan、Anita Midha、Pablo Morentin-Gutierrez、Jane E. Moore、Piotr Raubo、Graeme Robb

  DOI：10.1021/acs.jmedchem.7b00210

  日期：2017.4.13

  therapeutic potential for the treatment of diabetes, but few selective agonists have been reported. We identified an indazole-6-phenylcyclopropylcarboxylic acid series of GPR120 agonists and conducted SAR studies to optimize GPR120 potency. Furthermore, we identified a (S,S)-cyclopropylcarboxylic acid structural motif which gave selectivity against GPR40. Good oral exposure was obtained with some compounds

  GPR120激动剂具有治疗糖尿病的潜力，但很少有选择性激动剂的报道。我们确定了GPR120激动剂的吲唑-6-苯基环丙基羧酸系列，并进行了SAR研究，以优化GPR120的效力。此外，我们确定了（S，S）-环丙基羧酸结构基序，该结构基序对GPR40具有选择性。一些化合物显示出意外的高CNS渗透性，获得了良好的口服暴露。增加的MDCK外排用于鉴定化合物，例如33具有较低的中枢神经系统渗透性，并且在口服葡萄糖耐量研究中具有活性。在GPR120 null和野生型小鼠中观察到差异活性，表明该作用是通过涉及GPR120激动的机制起作用的。
• Biaryl piperazinyl-pyridine analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20070027155A1

  公开（公告）日：2007-02-01

  Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了公式为：其中变量如此处所述的Biaryl piperazinyl-pyridine类似物。这些化合物是配体，可用于调节体内或体外特定受体活性，并且在治疗与人类、家养伴侣动物和家畜动物的病理性受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的这些配体的方法。
• Discovery of AZD2716: A Novel Secreted Phospholipase A₂ (sPLA₂) Inhibitor for the Treatment of Coronary Artery Disease
  作者：Fabrizio Giordanetto、Daniel Pettersen、Ingemar Starke、Peter Nordberg、Mikael Dahlström、Laurent Knerr、Nidhal Selmi、Birgitta Rosengren、Lars-Olof Larsson、Jenny Sandmark、Marie Castaldo、Niek Dekker、Ulla Karlsson、Eva Hurt-Camejo

  DOI：10.1021/acsmedchemlett.6b00188

  日期：2016.10.13

  Expedited structure-based optimization of the initial fragment hit 1 led to the design of (R)-7 (AZD2716) a novel, potent secreted phospholipase A(2) (sPLA(2)) inhibitor with excellent preclinical pharmacokinetic properties across species, clear in vivo efficacy, and minimized safety risk. Based on accumulated profiling data, (R)-7 was selected as a clinical candidate for the treatment of coronary artery disease.